Short answer: GLP-1 drugs such as semaglutide (Ozempic, Wegovy), liraglutide (Saxenda) and tirzepatide (Mounjaro, Zepbound) help women with PMOS lose weight, but there is no good evidence yet that they reduce unwanted hair. A 2026 meta-analysis of 11 randomized trials found modest weight loss and too little data on hirsutism to draw any conclusion, and the one high-quality trial that scored hair growth found no change after 26 weeks.[1] None of these drugs is approved to treat PMOS or hirsutism.
GLP-1 receptor agonists are medicines that act like glucagon-like peptide-1, a hormone made in the gut. Several are approved for long-term weight management, mostly as weekly injections, and semaglutide is now also available as a tablet.[7][8] Because high insulin is one of the drivers of excess androgens (male-type hormones such as testosterone) in PMOS, many women hope these drugs will also calm unwanted facial and body hair. PMOS is the new name for polycystic ovary syndrome (PCOS), agreed in a global consensus published in The Lancet in May 2026.[3]
This article looks at what the trials actually measured, what the guidelines say, and the safety points that matter most if you have PMOS, especially around pregnancy and birth control. If you want the background on why insulin matters for hair, read our guide to insulin resistance and facial hair.
Do GLP-1 drugs like Ozempic reduce hirsutism?
Evidence: Limited Not as far as current studies can tell. Most GLP-1 trials in women with PCOS measured weight, blood sugar and hormones, not hair. The 2026 meta-analysis by Forslund and colleagues, which included 11 randomized controlled trials, concluded that evidence on hirsutism was insufficient and no pooled analysis was possible.[1]
The best single trial on this question compared liraglutide 1.8 mg a day with placebo for 26 weeks in about 70 Danish women with PCOS, higher weight and insulin resistance. Free testosterone and the free androgen index fell, and SHBG (sex hormone-binding globulin, a protein that keeps testosterone inactive) rose with liraglutide.[4] Yet hair scores on the Ferriman-Gallwey scale, the standard 0 to 36 hirsutism score, did not change in either group.[1] Two other trials, one with exenatide and one with beinaglutide, also found no change in hair scores.[4]
This gap between hormones and hair matters. A lower testosterone level on a blood test is not the same as less hair on your chin. Hair follicles change slowly, and most GLP-1 trials in PCOS lasted only 12 to 32 weeks.[1]
What do studies show on weight, testosterone and SHBG?
GLP-1 drugs reliably help with weight in women with PCOS, while their effect on androgens is inconsistent. Here is what the main reviews found:
| Outcome | What studies found | How sure we are |
|---|---|---|
| Body weight and BMI | 2026 meta-analysis (11 trials): BMI fell by 1.38 points more when a GLP-1 was added to other treatment, and by 2.18 points versus placebo.[1] 2025 meta-analysis (13 trials, 795 women): Weight fell by 3.57 kg more than with metformin or placebo.[5] | Low certainty, short trials |
| Total testosterone | No significant difference in the 2025 meta-analysis, where most comparisons were against metformin.[5] | Low |
| SHBG | No significant difference overall.[5] Rose with liraglutide versus placebo in one 26-week trial.[4] | Low |
| Free testosterone and free androgen index | Fell with liraglutide versus placebo in one trial,[4] and fell during semaglutide treatment in a small observational study.[4] | Low to very low |
| Hirsutism score | Not enough data to pool. The trials that measured it found no change.[1][4] | Very low |
| Periods | Two trials favored GLP-1 drugs over metformin for cycle regularity.[1] | Very low |
An earlier review, done for the 2023 international PCOS guideline, reached a similar conclusion: Published data on anti-obesity medicines in women with PCOS are “very limited,” and most of the benefit seen was on weight.[6]
Why would a weight-loss drug affect unwanted hair?
The theory runs through insulin. In PMOS, insulin resistance increases androgen production in the theca cells of the ovaries, and high insulin also reduces the liver’s production of SHBG, which leaves more free testosterone in circulation.[4] GLP-1 drugs improve insulin resistance and weight, so in principle they could lower androgen activity over time. The 2025 meta-analysis did find a significant drop in HOMA-IR, a common insulin resistance score.[5]
So far, though, that chain has not been shown to end in less hair. Weight loss from lifestyle change works the same way and produces only a small change in hair scores, which we cover in our insulin resistance article.
What about semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro)?
These are the drugs most people ask about, but they are the least studied in PMOS. Most randomized trials in the 2026 meta-analysis used older drugs, mainly exenatide and liraglutide.[1]
- Semaglutide: In a 2023 open-label study of 97 women with PCOS who had not lost weight with lifestyle changes, low-dose semaglutide (0.5 mg weekly) led to significant weight loss in almost 80% of them. A 2024 observational study of 25 women found that free testosterone and the free androgen index fell during treatment, but the other hormone and metabolic effects did not last after the drug was stopped.[4] Neither study measured hair growth as a main outcome.
- Tirzepatide: A 2025 review noted that data on tirzepatide in women with PCOS are lacking.[4] A placebo-controlled trial called PERIODS began in Germany in December 2025. It plans to enroll 198 women with PCOS and overweight or obesity for 72 weeks. Its main outcome is menstrual bleeding patterns, testosterone is a secondary outcome, and signs of androgen excess such as hair are only exploratory.[9]
In short, nobody yet knows whether the larger weight loss seen with semaglutide and tirzepatide translates into less unwanted hair.
Are GLP-1 drugs approved for PMOS or hirsutism?
No. In the US, Wegovy is approved to reduce cardiovascular risk, for long-term weight reduction and for a type of fatty liver disease,[7] and Zepbound is approved for long-term weight reduction and for obstructive sleep apnea in adults with obesity.[8] Neither label lists PCOS, PMOS or hirsutism.
The 2023 International PCOS Guideline gives anti-obesity medicines a conditional recommendation: Liraglutide, semaglutide and orlistat could be considered, together with active lifestyle changes, to manage higher weight in adults with PCOS, following the same rules as for the general population.[2] The guideline adds three practice points:[2]
- Use effective contraception when pregnancy is possible, because safety data in pregnancy are lacking.
- Increase the dose gradually to reduce stomach side effects.
- Discuss side effects, the likelihood of needing long-term treatment because weight often returns after stopping, and the limited long-term safety data.
The guideline does not mention tirzepatide.[2] For unwanted hair itself, it recommends the combined birth control pill as the first medicine, with anti-androgens added if the response is not good enough after at least 6 months.[2] You can read more in our guide to hirsutism medication.
Can you take GLP-1 drugs if you might get pregnant?
Only with reliable contraception and a plan for stopping. The official labels say:
- Semaglutide (Wegovy): Stop at least 2 months before you plan to become pregnant, because semaglutide stays in the body for a long time.[7]
- Tirzepatide (Zepbound): Stop when a pregnancy is recognized. Weight loss offers no benefit during pregnancy and may harm the baby.[8]
Tirzepatide and the birth control pill
Tirzepatide can make oral birth control less reliable. The Zepbound label advises people using oral hormonal contraceptives to switch to a non-oral method, or to add a barrier method such as condoms, for 4 weeks after starting the drug and for 4 weeks after each dose increase.[8] This matters for women with hirsutism, because the pill is often the main treatment for their hair. If you take spironolactone too, contraception is doubly important, since anti-androgens must not be taken in pregnancy.[2]
For oral semaglutide (Wegovy tablets), the label reports no clinically significant change in levels of the hormones in a typical combined pill.[7]
What are the common side effects of GLP-1 drugs?
Stomach and bowel problems are the most common. Both labels list nausea, diarrhea, vomiting, constipation and abdominal pain among side effects affecting at least 5% of users.[7][8] In the 2025 meta-analysis of women with PCOS, nausea, vomiting and dizziness were more common with GLP-1 drugs than with metformin or placebo.[5]
Both labels carry a boxed warning: These drugs caused thyroid C-cell tumors in rodents, and it is unknown whether this happens in humans. They must not be used by people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2).[7][8]
Who might benefit from a GLP-1 drug?
A GLP-1 drug makes the most sense for women with PMOS who meet the usual criteria for weight-loss medication, for example those with higher weight or blood sugar problems, as the guideline recommends.[2] In that case, the main goals are metabolic health and weight. Any effect on hair is a possible bonus, not a reason to start.
If unwanted hair is your main concern, the treatments with real evidence are the combined pill, anti-androgens and hair removal.[10] The Endocrine Society also advises against insulin-lowering drugs for hirsutism alone,[10] and a Cochrane review found metformin was no better than placebo for hair scores.[11] For hair removal options, see PMOS hair removal, and for supplements that target insulin, see inositol for hirsutism.
When should you see a doctor?
See a doctor before starting any GLP-1 drug. Only buy them on prescription from a licensed pharmacy. See a doctor promptly if:
- Your hair growth started suddenly or is getting worse within months
- You notice a deepening voice, an enlarged clitoris or other signs of virilization
- Your periods are irregular or have stopped
- You have severe or ongoing stomach pain, vomiting or signs of dehydration while taking a GLP-1 drug
Sudden or rapidly worsening hair growth can be a sign of a rare hormone-producing tumor and needs prompt checks.[10] Not sure who to see? Our which doctor tool can help, and PMOS facial hair explains the usual causes.
Frequently asked questions
Does Ozempic reduce facial hair?
There is no evidence that it does. No trial of semaglutide in PCOS has shown less facial hair, and the GLP-1 trials that scored hair growth found no change.[1][4]
Does semaglutide lower testosterone in women?
It may lower free testosterone in women with PCOS, based on one small observational study of 25 women.[4] Pooled trials of GLP-1 drugs found no significant change in total testosterone.[5]
Can Mounjaro make my birth control pill less effective?
Yes. Tirzepatide can reduce the effectiveness of oral contraceptives, so its label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.[8]
Is Wegovy approved for PCOS or PMOS?
No. It is approved for weight management, cardiovascular risk reduction and a type of fatty liver disease.[7] The international guideline says it could be considered for higher weight in PCOS, following general population rules.[2]
Will my hair get worse if I stop a GLP-1 drug?
Nobody has studied this for hair. Weight often returns after stopping,[2] and in one small study the hormone changes seen with semaglutide did not last after it was stopped.[4]
Key takeaways
- GLP-1 drugs help women with PMOS lose weight, but trials have not shown less unwanted hair.
- Some studies show lower free testosterone or higher SHBG, but a hormone change is not the same as less hair.
- No GLP-1 drug is approved for PMOS or hirsutism. The 2023 guideline supports them only for weight management.
- Stop semaglutide at least 2 months before a planned pregnancy, and use a non-oral or backup method of contraception with tirzepatide.
- For unwanted hair, the pill, anti-androgens and hair removal remain the treatments with real evidence.
Sources
- Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2026;194(3):S25-S39. PubMed 41701618
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. PubMed 37580314
- Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. PubMed 42119588
- Monney M, Mavromati M, Leboulleux S, Gariani K. Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review. Endocr Connect. 2025;14(5):e240529. PubMed 40066975
- Lin S, Deng Y, Huang J, et al. Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials. Sci Rep. 2025;15:16512. doi:10.1038/s41598-025-99622-4. Link
- Goldberg A, Graca S, Liu J, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5):e13704. PubMed 38355887
- US Food and Drug Administration. Wegovy (semaglutide) injection and tablets: Prescribing information (revised May 2026). Accessed October 2026. Link
- US Food and Drug Administration. Zepbound (tirzepatide) injection: Prescribing information (revised April 2026). Accessed October 2026. Link
- EU Clinical Trials Information System. A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS), EU CT 2024-515982-32-00. Accessed October 2026. Link
- Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257. PubMed 29522147
- van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;(4):CD010334. PubMed 25918921
This article is for education and is not medical advice. Talk to a doctor about diagnosis and treatment.